Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, offers her impression of the Phase 2 CAPTIVATE study investigating the BTK inhibitor ibrutinib plus venetoclax in the first-line treatment of chronic lymphocytic leukemia (CLL).
